Tradestie Institutional Equity Comparison Engine
PMI vs RCEL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RCEL Overall Edge
RCEL Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avita Medical, Inc. Common Stock (RCEL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, PMI trades at N/M Forward P/E with -248.1% operating margin (+38.6% YoY revenue) versus RCEL at 10.3x Forward P/E and -33.9% operating margin (+53.1% YoY). In options structure, PMI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against RCEL sits in CONSOLIDATION (14th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
RCEL
PMI N/M vs RCEL 10.3x Fwd P/E
Growth & Margin Winner
RCEL
Op Margin -248.1% vs -33.9% ยท YoY +38.6% vs +53.1%
Momentum & Technical Winner
RCEL
1Y +107.2% vs +304.8% ยท 52W Pos 34% vs 84%
Options & Structure Winner
RCEL
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (14th %ile IV)
PMI
NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap
$17.1M
1M Return
-34.58%
1Y Return
+107.24%
Forward P/E
N/M
Unified AI Score
48.4 / 100
HOLD
Tech 39.0
Fund 45.0
Flow 50.0
Mom 50.0
RCEL
NASDAQ
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.99
-4.99% 1D
Market Cap
$533.3M
1M Return
+4.58%
1Y Return
+304.81%
Forward P/E
10.3x
Unified AI Score
45.8 / 100
HOLD
Tech 41.0
Fund 44.0
Flow 67.0
Mom 31.1
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PMI +107.24%
RCEL +304.81%
Spread: +156.78 pp (RCEL Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PMI Revenue | RCEL Revenue | PMI Op. Margin | RCEL Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -1489.9% | RCEL |
| FY2019 | N/A | $10M | N/A | -466.4% | RCEL |
| FY2020 | N/A | $10M | N/A | -299.2% | RCEL |
| FY2021 | N/A | $30M | N/A | -90.8% | RCEL |
| FY2022 | N/A | $30M | N/A | -79.9% | RCEL |
| FY2023 | N/A | $50M | N/A | -85.1% | RCEL |
| FY2024 | $0M | $60M | -312.3% | -88.1% | RCEL |
| FY2025 | $0M | $70M | -268.4% | -59.4% | RCEL |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PMI | RCEL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $17.1M | $533.3M | Larger Scale | RCEL |
| Trailing P/E Ratio Valuation | 2.9x | 10.3x | Lower Multiple | PMI |
| Forward P/E Ratio Valuation | N/M | 10.3x | Lower Multiple | RCEL |
| Revenue Growth (YoY) Growth | +38.6% | +53.1% | Higher Growth | RCEL |
| Operating Margin (TTM) Profitability | -248.1% | -33.9% | Higher Margin | RCEL |
| Net Profit Margin Profitability | 0.0% | -42.6% | Higher Margin | PMI |
| Return on Equity (ROE) Capital Efficiency | 0.0% | -1746.3% | Higher ROE | PMI |
| 52-Week Range Position Momentum | 34% ($0โ$18) | 84% ($3โ$18) | Stronger Trend | RCEL |
| Beta / 30D Volatility Risk Regime | 54.06ฮฒ ยท 134% Vol | 1.59ฮฒ ยท 64% Vol | Lower Realized Risk | RCEL |
| Unified Institutional Score Composite Signal | 48.4 / 100 (HOLD) | 45.8 / 100 (HOLD) | Higher Composite | PMI |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PMI vs RCEL Buy Guide
PMI
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
RCEL
CONSOLIDATION
16d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PMI nor RCEL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.